plpro inhibitor

PLpro inhibitor is a potent papain-like protease (PLpro) inhibitor(IC50 of 2.6 uM)

PLpro/RBD-IN-1 is a dual inhibitor of SARS-CoV-2 PLpro and the spiny protein RBD, with anti-novel coronavirus activity, and is seen for the study of viral infections.

SARS-CoV-2-IN-69 (Compound 7E) is a potent, non-covalent inhibitor of the SARS-CoV-2 main protease (M^pro) with an EC50 of 7.4 μM and also inhibits the papain-like protease (PL^pro) [1].

SARS-CoV-2-IN-68 (compound 6C) is a covalent inhibitor of both SARS-CoV-2 PLpro and Mpro, exhibiting potent antiviral properties by targeting the Zn-finger domain of PLpro [1].

PLP_Snyder530 is a potent papain-like protease (PL pro ) inhibitor. PLP_Snyder530 induces conformational changes in SARS-COV-2 papain-like protease, inhibiting SARS-CoV-2 replication. PLP_Snyder530 can be used for SARS-CoV-2 research [1].

XR8-69 is a SARS-CoV-2 PLpro inhibitor. XR8-69 has a low micromolar antiviral effect in SARS-CoV-2 infected human cells.

SARS-CoV-2-IN-23 (compound GRL-0617) is an inhibitor of SARS-COV-2 papain-like protease (PLpro) (IC 50 = 2.3 μM) [1].

Mpro/PLpro-IN-1 (Compound 29) is a dual-acting inhibitor of SARS-CoV-2 protease.Mpro/PLpro-IN-1 is also a potent inhibitor of Mpro/PLpro, with micromolar inhibition of M pro (IC50:1.72 μM) and submicromolar inhibition of PL pro (IC50:0.67 μM). (IC50:0.67 μM).

XR8-89, a potent inhibitor of papain-like protease (PLpro), exhibits an IC50 value of 0.1 μM and effectively hinders SARS-CoV-2 replication by inducing conformational changes in the SARS-COV-2 papain-like protease. This compound holds potential for SARS-CoV-2 research applications [1].

Antiviral agent 25 (compound 6g), a novel non-peptide analog covalent inhibitor of SARS-CoV-2 3CL pro, exhibits robust inhibitory activity against both SARS-CoV-2 3CL pro and SARS-CoV-2 PL pro, with IC50 values of 0.118 µM and 0.448 µM, respectively. Furthermore, it demonstrates significant antiviral effects against SARS-CoV-2, achieving an EC50 value of 7.249 µM [1].

SIMR3030, a potent inhibitor of SARS-CoV-2 PLpro, possesses an IC50 of 0.0399 µg/mL and demonstrates antiviral activity by diminishing the expression of SARS-CoV spike, ORF1b, IFN-α, and IL-6 mRNA. Additionally, SIMR3030 has been shown to have a satisfactory safety profile in mice [1].

SP inhibitor 1 is an inhibitor of SARS-CoV-2 replication at non-toxic concentrations (0.3250<5.98 μM) in vitro. SP inhibitor 1 is a selective inhibitor of SARS-CoV-2 stinger protein (SP), acting on SP protein (IC50: 3.26 μM), Mpro protein (IC50>25 μM) and PLpro protein (IC50>25 μM), and has cellular antiviral effects. and PLpro protein (IC50>25 μM), and has cellular antiviral effects.

INSCoV-600K(1) is a potent Mpro(3CLpro) inhibitor. Proteases (PLpro and 3CLpro) are associated with viral transcription and replication. INSCoV-600K(1) has shown research potential against SARS-CoV-2 infection.

INSCoV-601I(1) is a potent Mpro(3CLpro) inhibitor. Proteases (PLpro and 3CLpro) are associated with viral transcription and replication. INSCoV-600I(1) has shown research potential against SARS-CoV-2 infection.

SARS-CoV-2-IN-24 is a potent inhibitor of papain-like proteases (PLpro) that induces conformational changes in SARS-COV-2 papain-like proteases, inhibits SARS-COV-2 replication, and can be used to study SARS-CoV-2.

SARS-CoV-2-IN-61 (compound 8i) is a potent inhibitor of the SARS-CoV-2 PLpro, exhibiting an IC50 of 16 µM and demonstrating antiviral activities [1].

INSCoV-614(1B) is a potent Mpro(3CLpro) inhibitor. Proteases (PLpro and 3CLpro) are associated with viral transcription and replication. INSCoV-614(1B) has shown research potential for SARS-CoV-2 infection.